Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225287 · ClinicalTrials.gov registry record · Phase 2
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
A Phase 2 study, sponsored by Ra Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT03225287 is a Phase 2 study that was terminated before completion, run by Ra Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT03225287, a Phase 2 study, was terminated before completion, sponsored by Ra Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
Interventions
- DRUG Zilucoplan (RA101495)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03225287
The ClinicalTrials.gov registry entry for NCT03225287 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ra Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zilucoplan (RA101495) is the first listed.
NCT03225287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03225287 about?
NCT03225287 is a clinical study titled "Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study". The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
What is the current status of trial NCT03225287?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2017-07-17. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT03225287?
The interventions under investigation include: Zilucoplan (RA101495) (DRUG).
Who is sponsoring clinical trial NCT03225287?
This trial is sponsored by Ra Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.